BRCA2 and ovarian cancer: CBC, OC, and nonbreast/ovarian cancer HRs remained similar after adjusting for chemotherapy, radiotherapy, and hormonal therapy (Data Supplement, Table S9), and after including females that tested negative for a PV in one gene after predictive testing, and were untested for PVs in the other gene, in the BRCA1/BRCA2 PV noncarrier group (Data Supplement, Table S10).